• 1. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 2. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 3. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 4. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 5. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577

• Other Chemical Reagents

Introduction to Nourseothricin sulfate (CAS No. 96736-11-7) in Modern Chemical Biology and Medicine

Nourseothricin sulfate, identified by the chemical identifier CAS No. 96736-11-7, is a compound of significant interest in the fields of chemical biology and pharmaceutical research. This peptide antibiotic, derived from the fermentation of *Streptomyces rochei*, has garnered attention for its potent biological activity and unique mechanism of action. The compound's structure, characterized by a cyclic decapeptide backbone, incorporates unusual amino acids such as norleucine and ornithine, which contribute to its remarkable stability and efficacy.

The sulfate salt form of Nourseothricin sulfate enhances its solubility in aqueous solutions, making it particularly useful for applications in biomedical research and drug development. Its primary mode of action involves the inhibition of bacterial protein synthesis by binding to the 30S ribosomal subunit, thereby disrupting the translation process. This mechanism distinguishes it from many conventional antibiotics, which often target different bacterial processes or cellular structures.

Recent advancements in synthetic chemistry have enabled the efficient production of Nourseothricin sulfate, reducing costs and improving scalability for industrial applications. Researchers have explored various synthetic pathways, including solid-phase peptide synthesis (SPPS) and enzymatic catalysis, to optimize yield and purity. These innovations have positioned Nourseothricin sulfate as a viable candidate for therapeutic development, particularly in addressing multidrug-resistant bacterial infections.

In clinical research, Nourseothricin sulfate has been investigated for its potential in treating Gram-positive bacterial infections, including those caused by methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant enterococci (VRE). Preliminary studies suggest that its broad-spectrum activity and low propensity for inducing resistance make it a promising alternative to traditional antibiotics. Additionally, its minimal impact on human cells has sparked interest in its use as a selective agent in cell culture applications.

The compound's unique chemical properties have also been leveraged in diagnostic tools and antimicrobial coatings. For instance, surface-modified nanoparticles functionalized with Nourseothricin sulfate have demonstrated effective bacterial inhibition on medical devices, reducing the risk of hospital-acquired infections. Furthermore, its stability under various pH conditions has been exploited in developing novel antimicrobial formulations for topical use.

From an academic perspective, Nourseothricin sulfate serves as a valuable tool for studying bacterial resistance mechanisms. By examining how bacteria adapt to its presence, researchers can gain insights into broader principles of antibiotic resistance and develop strategies to combat it. This includes exploring the role of efflux pumps, biofilm formation, and mutation-driven resistance in bacterial survival against peptide antibiotics.

The regulatory landscape for Nourseothricin sulfate reflects its growing importance in pharmaceuticals. Regulatory agencies have recognized its potential while emphasizing the need for comprehensive toxicological studies to ensure safety. Current research focuses on optimizing dosing regimens and delivery systems to maximize therapeutic efficacy while minimizing side effects. This includes investigating formulations that enhance bioavailability and target specific pathological conditions.

The future of Nourseothricin sulfate lies in interdisciplinary collaboration between chemists, biologists, and clinicians. By integrating synthetic chemistry with microbiology and pharmacology, researchers can develop next-generation antibiotics that address emerging threats posed by resistant pathogens. Furthermore, computational modeling techniques are being employed to predict structural modifications that could enhance activity or reduce toxicity.

In conclusion,Nourseothricin sulfate (CAS No. 96736-11-7) represents a significant advancement in antimicrobial therapy with broad implications for human health. Its unique structure,sulfate salt form,and mechanism of action position it as a cornerstone compound in modern chemical biology and medicine. As research continues to uncover new applications and refine production methods,Nourseothricin sulfate is poised to play an increasingly vital role in combating infectious diseases worldwide.

• 29266-98-6(4H-Imidazo[4,5-c]pyridin-4-one,2-[[4-O-(aminocarbonyl)-2-deoxy-2-[[2-[(iminomethyl)amino]acetyl]methylamino]-b-D-gulopyranosyl]amino]-3,3a,5,6,7,7a-hexahydro-7-hydroxy-5-methyl-,(3aS,7R,7aS)-)
• 3776-38-3(4H-Imidazo[4,5-c]pyridin-4-one,2-[[4-O-(aminocarbonyl)-2-[[(3S)-3-amino-6-[[(3S)-3,6-diamino-1-oxohexyl]amino]-1-oxohexyl]amino]-2-deoxy-b-D-gulopyranosyl]amino]-1,3a,5,6,7,7a-hexahydro-7-hydroxy-,(3aS,7R,7aS)-)
• 89020-28-0(Nbeta-Acetylstreptothricin D)
• 52599-88-9(4H-Imidazo[4,5-c]pyridin-4-one,2-[[2-[[6-[[6-(acetylamino)-3-amino-1-oxohexyl]amino]-3-amino-1-oxohexyl]amino]-4-O-(aminocarbonyl)-2-deoxy-b-D-gulopyranosyl]amino]-1,3a,5,6,7,7a-hexahydro-7-hydroxy-,[3aS-[2[R*(R*)],3aa,7a,7ab]]- (9CI))
• 103867-06-7(4H-Imidazo[4,5-c]pyridin-4-one,2-[[4-O-(aminocarbonyl)-2-deoxy-2-[[(3S)-3,6-diamino-1-oxohexyl]amino]-b-D-gulopyranosyl]amino]-1,3a,5,6,7,7a-hexahydro-5-methyl-,(3aS,7aR)- (9CI))
• 113402-06-5(4H-Imidazo[4,5-c]pyridin-4-one,2-[[6-O-(aminocarbonyl)-2-deoxy-2-[methyl[(methylamino)acetyl]amino]-b-D-gulopyranosyl]amino]-1,3a,5,6,7,7a-hexahydro-7-hydroxy-,(3aS,7R,7aS)- (9CI))
• 99237-10-2(4H-Imidazo[4,5-c]pyridin-4-one,2-[[4-O-(aminocarbonyl)-2-deoxy-2-[[(3S)-3,6-diamino-1-oxohexyl]amino]-b-D-gulopyranosyl]amino]-1,3a,5,6,7,7a-hexahydro-7-hydroxy-5-methyl-,(3aS,7R,7aS)- (9CI))
• 24543-64-4(4H-Imidazo[4,5-c]pyridin-4-one, 2-[[4-O-(aminocarbonyl)-2-deoxy-2-[[(3S,10S,17S,24S,31S,38S,45S)-3,10,17,24,31,38,45,48-octaamino-1,8,15,22,29,36,43-heptaoxo-7,14,21,28,35,42-hexaazaoctatetracont-1-yl]amino]-β-D-gulopyranosyl]amino]-3,3a,5,6,7,7a-hexahydro-7-hydroxy-, (3aS,7R,7aS)-)
• 29266-97-5(Antibiotic LL-AB 664; N5-De-Me)
• 102419-21-6(4H-Imidazo[4,5-c]pyridin-4-one,2-[[4-O-(aminocarbonyl)-2-deoxy-2-[(3,6-diamino-1-oxohexyl)amino]-b-D-gulopyranosyl]amino]-1,3a,5,6,7,7a-hexahydro-7-hydroxy-,trihydrochloride, [3aS-[2(R*),3aa,7a,7ab]]- (9CI))